Biogen (BIIB) Short-Term Debt issuances (2009 - 2011)
Biogen (BIIB) recorded quarterly Short-Term Debt issuances of -$7.5 million in Q3 2011, down 208.14% quarter-over-quarter from $7.0 million in Q2 2011, and down 2205.83% on a YoY basis from $356961.7 in Q3 2010.
Biogen (BIIB) Short-Term Debt issuances (2009 - 2011) Analysis & Trends
Biogen's Short-Term Debt issuances history runs 3 years deep, the most recent figure standing at -$7.5 million for Q3 2011.
- In Q3 2011, Short-Term Debt issuances fell 2205.83% year-over-year to -$7.5 million; the TTM figure through Sep 2011 stood at $6.2 million (down 16.31% YoY), while the FY2010 annual figure was $11.8 million, down 4.02% from the prior year.
- Short-Term Debt issuances was -$7.5 million for Q3 2011 at Biogen, down from $7.0 million in the prior quarter.
- In the past five years, Short-Term Debt issuances ranged from a high of $9.2 million in Q4 2010 to a low of -$7.5 million in Q3 2011.
- Historically, Short-Term Debt issuances has averaged $1.9 million across 3 years, with a median of $1.4 million in 2009.
- The sharpest annual moves came in 2010 and 2011: Short-Term Debt issuances soared 92.44% in 2010, then slumped 2205.83% in 2011.
- A 3-year view of Short-Term Debt issuances shows it stood at $4.8 million in 2009, then jumped by 92.44% to $9.2 million in 2010, then plunged by 181.75% to -$7.5 million in 2011.
- The last three Short-Term Debt issuances figures came in at -$7.5 million (Q3 2011), $7.0 million (Q2 2011), and -$2.5 million (Q1 2011), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ST Debt Issuance (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn | 1.61 Bn |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn | 1.78 Bn |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn | 12.44 Bn |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn | -499.00 Mn |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn | 1.06 Bn |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn | -127.00 Mn |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn | 321.00 Mn |
| 10 | Biogen | 28.36 Bn | 24.08 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | -7.52 Mn |
| Sep 30, 2011 | -7.52 Mn |
| Jun 30, 2011 | 6.95 Mn |
| Jun 30, 2011 | 6.95 Mn |
| Mar 31, 2011 | -2.47 Mn |
| Mar 31, 2011 | -2.47 Mn |
| Dec 31, 2010 | 9.20 Mn |
| Dec 31, 2010 | 9.20 Mn |
| Sep 30, 2010 | -326,000.00 |
| Sep 30, 2010 | -326,000.00 |
| Jun 30, 2010 | 4.74 Mn |
| Jun 30, 2010 | 4.74 Mn |
| Mar 31, 2010 | -1.83 Mn |
| Mar 31, 2010 | -1.83 Mn |
| Dec 31, 2009 | 4.78 Mn |
| Dec 31, 2009 | 4.78 Mn |
| Sep 30, 2009 | -28,000.00 |
| Sep 30, 2009 | -28,000.00 |
| Jun 30, 2009 | 6.16 Mn |
| Jun 30, 2009 | 6.16 Mn |